(UroToday.com) During the second day of the 2020 Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Mini Annual Scientific Meeting (ASM), two sessions examined key trials in ANZUP. The second of these focused on trials in bladder, urothelial, and penile cancers as well as renal cell carcinoma. In this session, Dr. Dickson Hayne […]
(UroToday.com) To begin the scientific portion of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Mini Annual Scientific Meeting (ASM) held 29 – 30 November 2020, Drs. Craig Gedye, Carole Harris, and Nicky Lawrence convened a session entitled Multi-Disciplinary Tumor (MDT) Master Games which sought to cover relevant and controversial topics in the management […]
(UroToday.com) At the Multi-disciplinary tumor (MDT) master games session at The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) 2020 Mini Annual Scientific Meeting (ASM), Dr. Laurence Krieger chaired a discussion of urothelial carcinoma. Joining him as panelists included Drs. Venu Chalasani, Tom Eade, Andrew Weickhardt, and Kathryn Schubach.
(UroToday.com) The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) 2020 mini Annual Scientific Meeting (ASM) virtual meeting featured a roundtable, multidisciplinary discussion of germ cell tumors chaired by medical oncologist Dr. James Lynam. Dr. Lynam’s panelists included medical oncologist Dr. Patricia Bastick, clinical nurse consultant Mrs. Lyndal Moore, and cardiothoracic surgeon Dr. Allen James.
Cabozantinib, an oral tyrosine kinase inhibitor against MET and vascular endothelial growth factor receptor 2 (VEGFR2), is an agent that was initially met with enormous enthusiasm by the prostate cancer community. The early data showed dramatic bone scan responses, where bone metastases would almost magically disappear after cabozantinib treatment on subsequent restaging bone scans. As […]
(UroToday.com) As part of The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) 2020 Mini Annual Scientific Meeting (ASM) Multi-Disciplinary Tumor (MDT) Master Games session, Dr. Alison Zhang chaired a session discussing renal cell carcinoma. Joining her as panelists included medical oncologist Dr. Howard Gurney, surgeon Dr. Nari Ahmadi, radiation oncologist Dr. Raymond […]
(UroToday.com) To begin the scientific portion of The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Mini Annual Scientific Meeting (ASM) held 29 – 30 November 2020, Drs. Craig Gedye, Carole Harris, and Nicky Lawrence convened a session entitled Multi-Disciplinary Tumor (MDT) Master Games which sought to cover relevant and controversial topics in the […]
(UroToday.com) To begin the scientific portion of The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Mini Annual Scientific Meeting (ASM) held 29 – 30 November 2020, Drs. Craig Gedye, Carole Harris, and Nicky Lawrence convened a session entitled Multi-Disciplinary Tumor (MDT) Master Games which sought to cover relevant and controversial topics in the management […]
Novel intravesical gene therapy given once every three months studied in patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer Phase 3 clinical trial met its primary endpoint with results demonstrating more than half of patients (53.4% of CIS ± Ta/T1 cohort) achieving a complete response (CR), all by three months1 45.5% of patients in the […]
Novel intravesical gene therapy given once every three months studied in patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer Phase 3 clinical trial met its primary endpoint with results demonstrating more than half of patients (53.4% of CIS ± Ta/T1 cohort) achieving a complete response (CR), all by three months1 45.5% of patients in the […]
